Gene therapy trial for rare heart condition halted before it began
NCT ID NCT06483802
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 25 times
Summary
This study was designed to test a new gene therapy called ASP2016 for heart problems in people with Friedreich Ataxia, a rare genetic disease that affects movement and the heart. The goal was to see if the treatment was safe and tolerable. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.